Crossmark

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes

Crossref DOI link: https://doi.org/10.1016/j.jacbts.2020.02.009

Published Print: 2020-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Franchi, Francesco

Rollini, Fabiana

Rivas, Jose

Rivas, Andrea

Agarwal, Malhar

Briceno, Maryuri

Wali, Mustafa

Nawaz, Ahmed

Silva, Gabriel

Shaikh, Zubair

Maailiki, Naji

Been, Latonya

Pineda, Andres M.

Suryadevara, Siva

Soffer, Daniel

Zenni, Martin M.

Bass, Theodore A.

Angiolillo, Dominick J.
Funding

Funding for this research was provided by:

Bristol-Myers Squibb

Medicines Company

Gilead Sciences

Eli Lilly and Company

Bayer Fund

St. Jude Medical

AstraZeneca

Scott R. MacKenzie Foundation

Edwards Lifesciences

Merck

Daiichi-Sankyo

CSL Behring

Amgen

Eisai

Boston Scientific Corporation

Medtronic

Boehringer Ingelheim

Abbott Laboratories

Sanofi
License Information

Text and Data Mining valid from 2020-05-01

Text and Data Mining valid from 2020-05-01

Version of Record valid from 2020-03-03
More Information

This article is maintained by: Elsevier

Article Title: Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes

Journal Title: JACC: Basic to Translational Science

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.jacbts.2020.02.009

Content Type: article

Copyright: © 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.